ANEW Medical Secures US Patent for Klotho Gene Therapy Targeting Neurodegenerative Diseases
ANEW Medical Secures US Patent for Klotho Gene Therapy Targeting Neurodegenerative Diseases
ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the grant and issuance of U.S. Patent No. 12,036,268 ("the 268 patent") covering the secreted RNA splice variant of the human Klotho gene, referred to as "s-KL", for the treatment of cognitive and neurodegenerative diseases.
美国生物技术公司ANEW MEDICAL, INC.（"ANEW"）（纳斯达克代码：WENA）致力于开发用于抗衰老和治疗与年龄相关疾病的细胞和基因治疗方案。今天，该公司宣布授予并颁发了美国专利No. 12,036,268（"268专利"），该专利覆盖人类Klotho基因的分泌型RNA剪接变体，称为"s-KL"，用于治疗认知和神经退行性疾病。
The human Klotho gene, sometimes referred to as the "anti-aging" gene, also controls many normal brain and neurologic functions. The Klotho gene-therapy patent in the U.S. is instrumental new intellectual property ("IP") protecting its development and commercialization in the U.S. ANEW previously announced that patents have already been granted and issued in Europe, China, and other Asian markets.
人类Klotho基因，有时被称为“抗衰老”基因，还控制着许多正常的大脑和神经系统功能。该基因在美国的基因疗法专利对其在美国的开发和商业化起到了至关重要的新知识产权（“IP”）保护。 ANEW先前宣布，在欧洲、中国和其他亚洲市场已经授予并颁发了专利。
ANEW's IP portfolio has been licensed on an exclusive worldwide basis from the Universitat Autònoma de Barcelona (UAB) and Institució Catalana De Recerca Estudis Avançats (ICREA) in Barcelona, Spain, and provides ANEW with rights to develop and commercialize novel genetic approaches for the treatment of neurodegenerative diseases, including Alzheimer's, amyotrophic lateral sclerosis (ALS or "Lou Gehrig's disease"), Parkinson's disease, and other age-related disorders. Replacing or augmenting the production of the gene product, s-KL, may also be used to support longevity.
ANEW的知识产权组合已经从西班牙巴塞罗那的Universitat Autònoma de Barcelona（UAB）和Institució Catalana De Recerca Estudis Avançats（ICREA）上以独家世界范围内授权方式获得，为ANEW提供了开发和商业化治疗神经退行性疾病，包括阿尔茨海默病、肌萎缩侧索硬化症（ALS或“卢·格里格病”）、帕金森病和其他与年龄相关的疾病的新型基因治疗方法的权利。替代或增加基因产物s-KL的生产也可以用于支持长寿。